AAD 2026Abstract 72973
Design of the REASSERT Study
A prospective, multi-country, noninterventional effectiveness and safety study evaluating remibrutinib in patients worldwide with chronic spontaneous urticaria (CSU)
Armstrong A, Saini S, Metz M, Zhao Z, Raftery T, Chapman-Rothe N, Khan I, Patil D, Giménez-Arnau AM
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Urticaria
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.601 · Not in PubMed: details from Crossref